In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
In the latest session, Cytokinetics Inc (NASDAQ: CYTK) closed at $62.53 down -4.30% from its previous closing price of $65.34. In other words, the price has decreased by -$4.30 from its previous closing price. On the day, 1.29 million shares were traded. CYTK stock price reached its highest trading level at $65.0 during the session, while it also had its lowest trading level at $62.2.
Ratios:
For a deeper understanding of Cytokinetics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.12 and its Current Ratio is at 6.12.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, UBS on January 24, 2024, Downgraded its rating to Neutral and sets its target price to $92 from $61 previously.
On January 05, 2024, Morgan Stanley Downgraded its rating to Equal-Weight which previously was Overweight and also upped its target price recommendation from $60 to $90.
On November 09, 2023, Goldman started tracking the stock assigning a Buy rating and target price of $50.Goldman initiated its Buy rating on November 09, 2023, with a $50 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Apr 25 ’24 when HENDERSON JOHN T sold 10,562 shares for $64.54 per share. The transaction valued at 681,671 led to the insider holds 32,070 shares of the business.
Malik Fady Ibraham sold 32,605 shares of CYTK for $2,422,918 on Apr 09 ’24. The EVP Research & Development now owns 138,567 shares after completing the transaction at $74.31 per share. On Mar 05 ’24, another insider, Malik Fady Ibraham, who serves as the EVP Research & Development of the company, sold 32,604 shares for $67.56 each. As a result, the insider received 2,202,606 and left with 138,973 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CYTK now has a Market Capitalization of 6833028096 and an Enterprise Value of 6582974464. For the stock, the TTM Price-to-Sale (P/S) ratio is 868.44. Its current Enterprise Value per Revenue stands at 874.233 whereas that against EBITDA is -13.592.
Stock Price History:
The Beta on a monthly basis for CYTK is 0.70, which has changed by 0.67595816 over the last 52 weeks, in comparison to a change of 0.24191546 over the same period for the S&P500. Over the past 52 weeks, CYTK has reached a high of $110.25, while it has fallen to a 52-week low of $25.98. The 50-Day Moving Average of the stock is -10.77%, while the 200-Day Moving Average is calculated to be 22.02%.
Shares Statistics:
For the past three months, CYTK has traded an average of 2.03M shares per day and 1109850 over the past ten days. A total of 101.64M shares are outstanding, with a floating share count of 101.15M. Insiders hold about 3.28% of the company’s shares, while institutions hold 108.26% stake in the company. Shares short for CYTK as of 1713139200 were 14042444 with a Short Ratio of 6.91, compared to 1710460800 on 14797215. Therefore, it implies a Short% of Shares Outstanding of 14042444 and a Short% of Float of 21.97.
Earnings Estimates
The current rating of Cytokinetics Inc (CYTK) is the result of assessments by 15.0 analysts actively engaged in evaluating its market dynamics.On average, analysts expect EPS of -$1.14 for the current quarter, with a high estimate of -$0.89 and a low estimate of -$1.35, while EPS last year was -$1.38. The consensus estimate for the next quarter is -$1.12, with high estimates of -$0.82 and low estimates of -$1.36.
Analysts are recommending an EPS of between -$3.43 and -$5.42 for the fiscal current year, implying an average EPS of -$4.45. EPS for the following year is -$3.29, with 15.0 analysts recommending between -$1.53 and -$5.0.
Revenue Estimates
Based on 15 analysts’ estimates, the company’s revenue will be $144.98M in the next fiscal year. The high estimate is $394.65M and the low estimate is $5M.
